<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721979</url>
  </required_header>
  <id_info>
    <org_study_id>9582</org_study_id>
    <secondary_id>NCI-2016-00221</secondary_id>
    <secondary_id>9582</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG1716037</secondary_id>
    <nct_id>NCT02721979</nct_id>
  </id_info>
  <brief_title>Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance</brief_title>
  <official_title>A Phase 2 Study of Apalutamide in Active Surveillance Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well apalutamide works in treating patients with prostate&#xD;
      cancer who are in active surveillance. Testosterone can cause the growth of prostate cancer&#xD;
      cells. Hormone therapy using androgen receptor antagonist apalutamide may fight prostate&#xD;
      cancer by blocking the use of testosterone by the tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      Patients receive apalutamide orally (PO) once daily (QD) for 90 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of the study treatment, patients are followed up at 180, 365, 545, and 730&#xD;
      days; and at years 3, 4 and 5 by medical record review.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Anticipated">December 13, 2021</completion_date>
  <primary_completion_date type="Actual">February 12, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative (i.e. no Residual Carcinoma) Site Directed and Systematic Prostate Biopsy Rate</measure>
    <time_frame>At 90 days</time_frame>
    <description>Negative rate will be presented as the percent of subjects with a negative repeat biopsy, and will be calculated as: (number of patients with a negative biopsy following 90-days of apalutamide) / (total number of patients enrolled on the study) x 100. A 1-sample chi-square test will be used to compare the proportion with a negative repeat biopsy to the null hypothesis value of 20% (above). The 95% confidence interval will be computed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Exiting Active Surveillance Due to Pathologic Reclassification</measure>
    <time_frame>At 2 years</time_frame>
    <description>The percentage of patients that exit active surveillance due to pathologic reclassification (e.g. increasing tumor volume or gleason score) will be computed along with its 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Exiting Active Surveillance for Any Reason</measure>
    <time_frame>At 2 years</time_frame>
    <description>Percentage of patients exiting active surveillance for any reason will be computed along with its 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Men Undergoing of Local Treatment</measure>
    <time_frame>At 2 years</time_frame>
    <description>Computed along with its 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Treatment Free Survival</measure>
    <time_frame>Up to 730 days</time_frame>
    <description>Kaplan-Meier methods and 95% confidence interval will be estimated using Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific Antigen Progression Rate</measure>
    <time_frame>At 2 years</time_frame>
    <description>Prostate-specific antigen progression rate will be defined per Prostate Cancer Working Group 2 criteria (i.e. confirmed rising prostate-specific antigen &gt;= 2 ng/mL at least one week apart) and will be computed along with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific Antigen Progression Free Survival as Defined by the Prostate Cancer Working Group 2 Criteria</measure>
    <time_frame>At 2 years</time_frame>
    <description>Prostate-specific antigen progression free survival will be estimated using Kaplan-Meier methods and 95% confidence interval will be estimated using Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Radiographic Disappearance of Magnetic Resonance Imaging Detectable Prostate Cancer</measure>
    <time_frame>Baseline to up to 90 days</time_frame>
    <description>This calculates the percentage of participants with radiographic disappearance of magnetic resonance imaging detectable prostate cancer. This is only in patients with a baseline nodule that is Prostate Imaging Reporting and Data System 3 or more and &gt; 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 730 days</time_frame>
    <description>As assessed by National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Adverse Events</measure>
    <time_frame>Up to 730 days</time_frame>
    <description>As assessed by National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: FACT-P Assessment</measure>
    <time_frame>Baseline to up to 730 days</time_frame>
    <description>As assessed using the Functional Assessment of Cancer Therapy-Prostate surveys. Functional Assessment of Cancer Therapy-Prostate is a validated quality of life survey specific for patients with prostate cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: SF-36 Assessment</measure>
    <time_frame>Baseline to up to 730 days</time_frame>
    <description>As assessed using the Short Form-36 survey. Short Form-36 is a validated quality of life survey. This is a generic survey to assess an individual's overall well-being, and is not specific to one disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (apalutamide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (apalutamide)</arm_group_label>
    <other_name>ARN 509</other_name>
    <other_name>ARN-509</other_name>
    <other_name>ARN509</other_name>
    <other_name>JNJ 56021927</other_name>
    <other_name>JNJ-56021927</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (apalutamide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (apalutamide)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (apalutamide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have signed an informed consent document&#xD;
&#xD;
          -  Be willing/able to adhere to the prohibitions and restrictions specified in this&#xD;
             protocol&#xD;
&#xD;
          -  Written authorization for use and release of health and research study information has&#xD;
             been obtained&#xD;
&#xD;
          -  Life expectancy &gt;= 10 years (as determined by the treating physician)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate as documented by a minimum 12&#xD;
             core prostate biopsy completed within 1-year of enrollment (note: most recent prostate&#xD;
             biopsy must have demonstrated prostatic adenocarcinoma)&#xD;
&#xD;
          -  Favorable risk prostate cancer as defined by:&#xD;
&#xD;
               -  Very low-risk:&#xD;
&#xD;
                    -  Clinical stage T1c disease&#xD;
&#xD;
                    -  PSA density (PSAD) &lt; 0.15 ng/mL&#xD;
&#xD;
                    -  Gleason score 6&#xD;
&#xD;
                    -  =&lt; 2 core biopsies with =&lt; 50% involvement of any biopsy core with cancer,&#xD;
                       or unilateral disease =&lt; 2 core biopsies with any percentage involvement OR&#xD;
&#xD;
               -  Low risk:&#xD;
&#xD;
                    -  Clinical stage =&lt; T2a&#xD;
&#xD;
                    -  PSA &lt; 15 ng/mL&#xD;
&#xD;
                    -  Gleason score 6 OR&#xD;
&#xD;
               -  Low-intermediate risk:&#xD;
&#xD;
                    -  Clinical stage T1c&#xD;
&#xD;
                    -  PSA &lt; 15 ng/ml&#xD;
&#xD;
                    -  Gleason 3+4 present in =&lt; 50% of one core/site as detected by systematic&#xD;
                       biopsy or MRI/transrectal ultrasound (TRUS) fusion guided biopsy&#xD;
&#xD;
                    -  Gleason 6 disease in all other cores / sites&#xD;
&#xD;
          -  Willing and qualified for active surveillance at Johns Hopkins or the University of&#xD;
             Washington&#xD;
&#xD;
          -  Serum testosterone &gt;= 150 ng/dL&#xD;
&#xD;
          -  Able to swallow the study drugs whole as a tablet&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL, (at screening), independent of transfusion and/or growth&#xD;
             factors within 3 months prior to registration&#xD;
&#xD;
          -  Platelet count &gt;= 100,000 x 10^9/uL (at screening) independent of transfusion and/or&#xD;
             growth factors within 3 months prior to registration&#xD;
&#xD;
          -  Serum albumin &gt;= 3.0 g/dL (at screening)&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) &gt;= 45 mL/min (at screening)&#xD;
&#xD;
          -  Serum potassium &gt;= 3.5 mmol/L (at screening)&#xD;
&#xD;
          -  Serum total bilirubin =&lt; 1.5 x upper limit of normal (ULN) (at screening) (note: in&#xD;
             subjects with Gilbert's syndrome, if total bilirubin is &gt; 1.5 x ULN, measure direct&#xD;
             and indirect bilirubin and if direct bilirubin is =&lt; 1.5 x ULN, subject may be&#xD;
             eligible)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &lt; 2.5 Ã— ULN (at&#xD;
             screening)&#xD;
&#xD;
          -  Medications known to lower the seizure threshold must be discontinued or substituted&#xD;
             at least 4 weeks prior to study entry&#xD;
&#xD;
          -  Agrees to use a condom (even men with vasectomies) and another effective method of&#xD;
             birth control if he is having sex with a woman of childbearing potential or agrees to&#xD;
             use a condom if he is having sex with a woman who is pregnant while on study drug and&#xD;
             for 3 months following the last dose of study drug; must also agree not to donate&#xD;
             sperm during the study and for 3 months after receiving the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation&#xD;
             therapy, brachytherapy)&#xD;
&#xD;
          -  Prior use of ARN-509 (apalutamide)&#xD;
&#xD;
          -  Have known allergies, hypersensitivity, or intolerance to ARN-509 (apalutamide) or its&#xD;
             excipients&#xD;
&#xD;
          -  Prior or ongoing systemic therapy for prostate cancer including, but not limited to:&#xD;
&#xD;
               -  Hormonal therapy (e.g. leuprolide, goserelin, triptorelin)&#xD;
&#xD;
               -  Cytochrome P450 (CYP)-17 inhibitors (e.g. abiraterone, ketoconazole)&#xD;
&#xD;
               -  Antiandrogens (e.g. bicalutamide, nilutamide)&#xD;
&#xD;
               -  Second generation antiandrogens (e.g. enzalutamide)&#xD;
&#xD;
               -  Immunotherapy (e.g. sipuleucel-T, ipilimumab)&#xD;
&#xD;
               -  Chemotherapy (e.g. docetaxel, cabazitaxel)&#xD;
&#xD;
          -  Have any condition that, in the opinion of the investigator, would compromise the&#xD;
             well-being of the subject or the study or prevent the subject from meeting or&#xD;
             performing study requirements&#xD;
&#xD;
          -  History of any of the following:&#xD;
&#xD;
               -  Seizure or known condition that may pre-dispose to seizure (including but not&#xD;
                  limited to prior stroke, transient ischemic attack, loss of consciousness within&#xD;
                  1 year prior to registration, brain arteriovenous malformation; or intracranial&#xD;
                  masses such as schwannomas and meningiomas that are causing edema or mass effect)&#xD;
&#xD;
               -  Severe or unstable angina, myocardial infarction, symptomatic congestive heart&#xD;
                  failure, arterial or venous thromboembolic events (e.g., pulmonary embolism,&#xD;
                  cerebrovascular accident including transient ischemic attacks), or clinically&#xD;
                  significant ventricular arrhythmias within 6 months prior to registration&#xD;
&#xD;
               -  Any condition that in the opinion of the investigator, would preclude&#xD;
                  participation in this study&#xD;
&#xD;
          -  Current evidence of any of the following:&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Gastrointestinal disorder affecting absorption&#xD;
&#xD;
               -  Active infection (e.g. human immunodeficiency virus [HIV] or viral hepatitis) or&#xD;
                  other medical condition that would make prednisone/prednisolone (corticosteroid)&#xD;
                  use contraindicated&#xD;
&#xD;
               -  Any condition that in the opinion of the investigator, would preclude&#xD;
                  participation in this study&#xD;
&#xD;
          -  The use of drugs known to lower the seizure threshold, including: atypical&#xD;
             antipsychotics (e.g. clozapine, olanzapine, risperidone, ziprasidone), bupropion,&#xD;
             lithium, meperidine, pethidine, phenothiazine antipsychotics (e.g. chlorpromazine,&#xD;
             mesoridazine, thioridazine), and tricyclic antidepressants (e.g. amitriptyline,&#xD;
             desipramine, doxepin, imipramine, maprotiline, mirtazapine)&#xD;
&#xD;
          -  The use of strong CYP3A4 inhibitors, including: itraconazole, clarithromycin,&#xD;
             erythromycin, diltiazem, verapamil, delavirdine, atazanavir, indinavir, nefazodone,&#xD;
             nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit juice (or&#xD;
             grapefruits)&#xD;
&#xD;
               -  Note: If a patient is on a strong CYP3A4 inhibitor, they can be reconsidered for&#xD;
                  enrollment if they can safely stop said medication; a two week or 5 half-lives,&#xD;
                  whichever is longer, washout will be required prior to enrolling on study;&#xD;
                  subject may not resume medication while receiving apalutamide&#xD;
&#xD;
          -  Strong CYP3A4 inducers, including: phenytoin, carbamazepine, rifampin, rifabutin,&#xD;
             rifapentine, phenobarbital, efavirenz, tipranavir, St. John's wort&#xD;
&#xD;
             **Note: If a patient is on a strong CYP3A4 inhibitor, they can be reconsidered for&#xD;
             enrollment if they can safely stop said medication; a two week or 5 half-lives,&#xD;
             whichever is longer, washout will be required prior to enrolling on study; subject may&#xD;
             not resume medication while receiving apalutamide&#xD;
&#xD;
          -  Any psychological, familial, sociological, or geographical condition that could&#xD;
             potentially interfere with compliance with the study protocol and follow-up schedule&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Schweizer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <results_first_submitted>February 4, 2021</results_first_submitted>
  <results_first_submitted_qc>March 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2021</results_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Michael Schweizer</investigator_full_name>
    <investigator_title>Assistant Professor, Division of Medical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 26, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02721979/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02721979/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The screening study procedures are conducted within 30 days prior to enrollment. The only exception to this would be the surveillance prostate biopsy.</recruitment_details>
      <pre_assignment_details>24 subjects signed consent for this study, but only 23 were eligible to enter into the treatment phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Apalutamide</title>
          <description>Day 1 until Day 90. Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Apalutamide: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There are 24 participants who signed the consent form, and only 23 progressed into the treatment phase. One patient was a screen fail.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Apalutamide)</title>
          <description>Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Apalutamide: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with very low risk disease at baseline</title>
          <description>Patients deemed to have very low risk disease based on NCCN criteria at the time of enrollment.</description>
          <population>Only patients that did not screen fail are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Negative (i.e. no Residual Carcinoma) Site Directed and Systematic Prostate Biopsy Rate</title>
        <description>Negative rate will be presented as the percent of subjects with a negative repeat biopsy, and will be calculated as: (number of patients with a negative biopsy following 90-days of apalutamide) / (total number of patients enrolled on the study) x 100. A 1-sample chi-square test will be used to compare the proportion with a negative repeat biopsy to the null hypothesis value of 20% (above). The 95% confidence interval will be computed.</description>
        <time_frame>At 90 days</time_frame>
        <population>These are patients that had 90 days of treatment and had post-treatment biopsies.</population>
        <group_list>
          <group group_id="O1">
            <title>Apalutamide</title>
            <description>Day 1 until Day 90. Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Apalutamide: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Negative (i.e. no Residual Carcinoma) Site Directed and Systematic Prostate Biopsy Rate</title>
          <description>Negative rate will be presented as the percent of subjects with a negative repeat biopsy, and will be calculated as: (number of patients with a negative biopsy following 90-days of apalutamide) / (total number of patients enrolled on the study) x 100. A 1-sample chi-square test will be used to compare the proportion with a negative repeat biopsy to the null hypothesis value of 20% (above). The 95% confidence interval will be computed.</description>
          <population>These are patients that had 90 days of treatment and had post-treatment biopsies.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="37" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Exiting Active Surveillance Due to Pathologic Reclassification</title>
        <description>The percentage of patients that exit active surveillance due to pathologic reclassification (e.g. increasing tumor volume or gleason score) will be computed along with its 95% confidence interval.</description>
        <time_frame>At 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Exiting Active Surveillance for Any Reason</title>
        <description>Percentage of patients exiting active surveillance for any reason will be computed along with its 95% confidence interval.</description>
        <time_frame>At 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Men Undergoing of Local Treatment</title>
        <description>Computed along with its 95% confidence interval.</description>
        <time_frame>At 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Treatment Free Survival</title>
        <description>Kaplan-Meier methods and 95% confidence interval will be estimated using Greenwood's formula.</description>
        <time_frame>Up to 730 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate-specific Antigen Progression Rate</title>
        <description>Prostate-specific antigen progression rate will be defined per Prostate Cancer Working Group 2 criteria (i.e. confirmed rising prostate-specific antigen &gt;= 2 ng/mL at least one week apart) and will be computed along with 95% confidence interval.</description>
        <time_frame>At 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate-specific Antigen Progression Free Survival as Defined by the Prostate Cancer Working Group 2 Criteria</title>
        <description>Prostate-specific antigen progression free survival will be estimated using Kaplan-Meier methods and 95% confidence interval will be estimated using Greenwood's formula.</description>
        <time_frame>At 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Radiographic Disappearance of Magnetic Resonance Imaging Detectable Prostate Cancer</title>
        <description>This calculates the percentage of participants with radiographic disappearance of magnetic resonance imaging detectable prostate cancer. This is only in patients with a baseline nodule that is Prostate Imaging Reporting and Data System 3 or more and &gt; 5 mm.</description>
        <time_frame>Baseline to up to 90 days</time_frame>
        <population>Only 1 patient had paired MRI at baseline and again at post-treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Apalutamide</title>
            <description>Day 1 until Day 90. Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Apalutamide: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Radiographic Disappearance of Magnetic Resonance Imaging Detectable Prostate Cancer</title>
          <description>This calculates the percentage of participants with radiographic disappearance of magnetic resonance imaging detectable prostate cancer. This is only in patients with a baseline nodule that is Prostate Imaging Reporting and Data System 3 or more and &gt; 5 mm.</description>
          <population>Only 1 patient had paired MRI at baseline and again at post-treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events</title>
        <description>As assessed by National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.</description>
        <time_frame>Up to 730 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Adverse Events</title>
        <description>As assessed by National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.</description>
        <time_frame>Up to 730 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: FACT-P Assessment</title>
        <description>As assessed using the Functional Assessment of Cancer Therapy-Prostate surveys. Functional Assessment of Cancer Therapy-Prostate is a validated quality of life survey specific for patients with prostate cancer.</description>
        <time_frame>Baseline to up to 730 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: SF-36 Assessment</title>
        <description>As assessed using the Short Form-36 survey. Short Form-36 is a validated quality of life survey. This is a generic survey to assess an individual's overall well-being, and is not specific to one disease.</description>
        <time_frame>Baseline to up to 730 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 1 until Day 90.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Apalutamide</title>
          <description>Day 1 until Day 90. Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Apalutamide: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired Vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rectal Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Increased Bowel Movement Frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Muscositis Oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Stomach Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue/Decreased Energy</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Flu Like Symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased/Elevated TSH</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight Loss/Anorexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cramp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tingling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Postural Dizziness/Balance Changes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Libido Decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Labile Mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cognitive Disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Memory Impairment/Forgetfulness/Amnesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Brain Fog</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Concentration Impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Decreased Mental Acuity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Lower Urinary Tract Symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dribbling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynecomastia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nipple Sensitivity/Tenderness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Mastodynia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Breast Tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Ejaculation Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nipple Itchiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Perceived Shrinking of Genitals</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Testicle Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection Symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Chest Tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lack of Body Odor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Burning Sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Painful Callus Bumps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Warmer Body</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Schweizer</name_or_title>
      <organization>University of Washington</organization>
      <phone>(206) 606-6252</phone>
      <email>schweize@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

